Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adenosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 known ✓ | P30542 | 3/20 | 0.89 |
| ▸ | ADORA3 known ✓ | P0DMS8 | 3/20 | 0.89 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 0.89 |
| ▸ | ADORA2B known ✓ | P29275 | 1/20 | 0.89 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.89 |
| ▸ | DPP4 | P27487 | 1/20 | 0.89 |
| ▸ | MEN1 | O00255 | 1/20 | 0.89 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.89 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.89 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.89 |
| ▸ | GAPDH | P04406 | 1/20 | 0.89 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.89 |
| ▸ | STAT6 | P42226 | 1/20 | 0.89 |
| ▸ | PI4KA | P42356 | 1/20 | 0.89 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.89 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.89 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.89 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.89 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.89 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine SCHEMBL6242700 | 1.00 | ADORA1 (0.89) | ADORA1SMN1; SMN2ADORA3DPP4MEN1 | |
| Adenosine SCHEMBL9171507 | 1.00 | ADORA1 (0.89) | ADORA1SMN1; SMN2ADORA3DPP4MEN1 | |
| Adenosine SCHEMBL3046213 | 1.00 | ADORA1 (0.89) | ADORA1SMN1; SMN2ADORA3DPP4MEN1 | |
| Adenosine SCHEMBL459769 | 1.00 | ADORA1 (0.89) | ADORA1SMN1; SMN2ADORA3DPP4MEN1 | |
| Adenosine SCHEMBL1746637 | 1.00 | ADORA1 (0.89) | ADORA1SMN1; SMN2ADORA3DPP4MEN1 | |
| Adenosine SCHEMBL50788 | 1.00 | ADORA1 (0.89) | ADORA1SMN1; SMN2ADORA3DPP4MEN1 | |
| Adenosine SCHEMBL468212 | 1.00 | ADORA1 (0.89) | ADORA1SMN1; SMN2ADORA3DPP4MEN1 | |
| Adenosine SCHEMBL1744578 | 1.00 | ADORA1 (0.89) | ADORA1SMN1; SMN2ADORA3DPP4MEN1 | |
| Vidarabine SCHEMBL7103173 | 1.00 | ADORA1 (0.89) | ADORA1SMN1; SMN2ADORA3DPP4MEN1 | |
| Adenosine SCHEMBL9147194 | 1.00 | ADORA1 (0.89) | ADORA1SMN1; SMN2ADORA3DPP4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250064856-A1 | METHODS FOR ADMINISTERING PLATELET DERIVATIVE COMPOSITIONS TO SUBJECTS AFFLICTED WITH HERMANSKY PUDLAK SYNDROME OR BERNARD SOULIER SYNDROME | CELLPHIRE, INC. (US) | 2025-02-27 | — | — | US | claimed |
| US-20240219387-A1 | APPARATUS AND METHODS USING TETHERED ENZYMES FOR THE DETECTION OF THE ENZYMATIC ACTIVITY OF BIOMARKERS | TETMEDICAL INC (US) | 2024-07-04 | — | — | US | claimed |
| CN-117882603-A | Method for regulating and controlling morphology index and physiological index of cork oak seedlings | 曲阜师范大学 | 2024-04-16 | — | — | CN | claimed |
| WO-2023220739-A1 | PLATELET DERIVATIVE COMPOSITIONS FOR USE IN SUBJECTS AFFLICTED WITH HERMANSKY PUDLAK SYNDROME OR BERNARD SOULIER SYNDROME | CELLPHIRE, INC. (US) | 2023-11-16 | — | — | WO | claimed |
| US-20230149467-A1 | PLATELET DERIVATIVE COMPOSITIONS, AND METHODS OF MAKING AND USING SUCH COMPOSITIONS | CELLPHIRE, INC. (US) | 2023-05-18 | — | — | US | claimed |
| WO-2023081804-A1 | PLATELET DERIVATIVE COMPOSITIONS, AND METHODS OF MAKING AND USING SUCH COMPOSITIONS | CELLPHIRE, INC. (US) | 2023-05-11 | — | — | WO | claimed |
| EP-4153322-A1 | COUPLED TERPENE CONJUGATE | Laboratoires Eriger (FR) | 2023-03-29 | — | — | EP | claimed |
| EP-4291664-B1 | SITE-SPECIFIC GENOME MODIFICATION TECHNOLOGY | UNIV NORTH CAROLINA STATE (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260126455-A1 | Methods and Dosing Regimens for Preventing or Delaying Onset of Alzheimer's Disease and Other Forms of Dementia and Mild Cognitive Impairment | ZACHRIEL NEUROSCIENCES LLC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4731002-A2 | SYSTEMS FOR PRODUCTION OF PRODUCTS TO PROMOTE NITROGEN USE EFFICIENCY IN PLANTS | Tenfold Technologies, LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| WO-2026043538-A1 | SYSTEM AND METHOD FOR BODY CONDITION DIAGNOSIS AND THERAPEUTIC STIMULUS INTERACTION THROUGH SMART FABRIC | MATRIX ENERGETICS, LLC (US) | 2026-02-26 | — | — | WO | disclosed |
| US-20260000781-A1 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | CIDARA THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250302880-A1 | PLATELET DERIVATIVE COMPOSITIONS IN THE FORM OF A POWDER | CELLPHIRE, INC. (US) | 2025-10-02 | — | — | US | disclosed |
| US-20100210654-A1 | NOVEL P2Y12 RECEPTOR ANTAGONISTS | RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITÄT BONN (DE) | 2010-08-19 | — | — | US | disclosed |
| EP-2129653-A2 | NOVEL P2Y12 RECEPTOR ANTAGONISTS | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008107211-A2 | NOVEL P2Y12 RECEPTOR ANTAGONISTS | RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITÄT BONN (DE) | 2008-09-12 | — | — | WO | disclosed |
| EP-1967513-A1 | Novel P2Y12 receptor antagonists | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2008-09-10 | — | — | EP | disclosed |
| US-20060105375-A1 | Bioretrosynthetic methods for preparing products and compositions related thereto | VANDERBILT UNIVERSITY | 2006-05-18 | — | — | US | disclosed |
| CN-1065757-C | Application of theachrome in preparing medicine for hyperuricemia | JAINGXI PROV GREEN INDUSTRY GR (CN) | 2001-05-16 | — | — | CN | disclosed |
| CN-1207919-A | Application of theachrome in preparing medicine for hyperuricemia | JIANGXI PROV GREEN INDUSTRY GR (CN) | 1999-02-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210654-A1 | NOVEL P2Y12 RECEPTOR ANTAGONISTS | P2RY12, P2RY11, P2RY13 | ADORA1 36/4885ADORA3 40/4885ADORA2A 32/4885 |
| US-20260126455-A1 | Methods and Dosing Regimens for Preventing or Delaying Onset of Alzheimer's Disease and Other Forms of Dementia and Mild Cognitive Impairment | CHRNA7, CHRNA9, CHRNA6 | ADORA1 64/4885ADORA3 97/4885ADORA2A 85/4885 |
| US-20260000781-A1 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | FCGR2A, FCGR1A, FCGR3B | ADORA1 82/4885ADORA3 73/4885ADORA2A 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.